Determinant components of newly onset versus improved metabolic syndrome in a population of Iran by Lankarani, Kamran Bagheri et al.
1
Vol.:(0123456789)
Scientific Reports |        (2020) 10:19563  | https://doi.org/10.1038/s41598-020-76531-2
www.nature.com/scientificreports
Determinant components of newly 
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This study aimed to determine the risk factors related to regression and progression of metabolic 
syndrome, in a 4-year cohort study. A total of 540 individuals (≥ 18 years old) participated in both 
phase of the study. Participants were categorized into 3 categories of regressed, progressed and 
unchanged metabolic syndrome (MetS). Demographic, anthropometric and biochemical parameters 
were assessed for each individual in both phase. Variables differences (delta: Δ) between the two 
phase of study were calculated. Unchanged group was considered as baseline category. Based on 
IDF, MetS had been regressed and progressed in 42 participants (7.7%) and 112 (20.7%) participants 
respectively, in the second phase. More than 47% of people, whose MetS regressed, experienced also 
NAFLD regression. Results of multiple variable analysis revealed that increased age, positive Δ-TG, 
and Δ-FBS, significantly increased the odds of MetS progression based on IDF and ATP III definitions, 
while negative Δ-HDL and Δ-neutrophil to lymph ration increased the odds of progression. On the 
other hand, negative Δ-TG and positive Δ-HDL significantly increased the odds of Mets regression 
based of both IDF and ATP III. Management of hypertriglyceridemia, hyperglycemia, and HDL is a 
critical, non-invasive and accessible approach to change the trend of MetS.
Metabolic syndrome (MetS) as a non-communicable disease (NCD) had become epidemic in many countries 
of the  world1. MetS is highly prevalent with multidimensional characteristics and a collection of abnormalities 
such as obesity, hypertension, dyslipidemia, and high blood  glucose2.
Over the past 20 years, population of people with MetS, has significantly increased, which is directly associated 
to the global epidemic of obesity and diabetes. This is in addition to elevated threat of diabetes and cardiovascular 
disorders that arise from the  MetS3 and influences more than 25% of the world  population4.
The description by the Adult Treatment Panel III-2005 (ATP III) seems to be the most internationally accepted 
description. In 2009, the International Diabetes Federation (IDF) and the American Heart Association/National 
Heart, Lung and Blood Institute standardized their criteria for defining  MetS5. The prevalence of MetS varies, 
based on the criteria used to define it. For instance, a study in Iran revealed the frequency of MetS to be 34.7% 
based on ATP III criteria, 37.4% based on IDF description, and 41.6% according to ATP III/AHA/NHLBI 
 criteria1. In a systematic review and meta-analysis, according to ATP III criteria, MetS prevalence amongst people 
of Iran who were 20 years old or older was 23.8% and for under 20 years old was 10.9%5.
MetS risk factors were investigated in different studies. Central obesity was significantly associated with MetS 
 mechanisms6, independent of insulin  resistance7. Apart from the accessible intervention approaches, alterations 
such as suitable diet, regular exercise, anti-obesity medication and bariatric operation, and failure to manage 
MetS prevalence and its associated complications depend on the disease nature and patients not following the 
foregoing  strategies8. Individuals with MetS are at higher risk of developing coronary artery disease (CAD). 
Coronary heart disease (CHD) were assessed by Framingham algorithms over a decade, and it was shown that 
many CHD incidences in MetS patients were prevented by controlling lipids and/or blood  pressure9. This study 
is among scarce studies that assessed factors affect the progression and regression of the MetS have not been 
reported in any longitudinal study. Hence, this study aimed to investigate the risks related to regression and 
progression of MetS in a 4-year cohort study.
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Results
Total 540 participants completed both phase. Among all, 308 participants were female (56.9%). Mean for age 
and BMI were 43.4 ± 12.6 years, and 26.4 ± 4.3 kg/m2 respectively. Only 11.3% of the studied population had 
university education and 88% were married. Prevalence of metabolic syndrome based on IDF (and ATPIII) 
criteria in the first and second phase of the study, was 21.4% (22.2%) and 34.4% (36%), respectively. Based on 
IDF criteria, MetS had improved in 42 participants (7.7%) while 112 (20.7%) of the participants developed 
MetS after the second phase. These percentages were 42 (7.7%) and 117 (21.6%), respectively based on ATP III. 
Age, education, and employment status were significantly different between the three groups. Gender, marital 
status, physical activity and tobacco smoking and alcohol consumption were not significantly different between 
groups. All demographic correlates of MetS, based on IDF definition and ATP III are shown in Table1. Further-
more, para-clinical correlates of MetS was assessed based on the two criteria. Based on IDF, Δ-BMI, and Δ-WC, 
Δ-TG, Δ-FBS, Δ-SBP, Δ-DBP, Δ-lymphocyte and Δ-NLR were significantly different between the three groups 
of “Un-changed”, “Regressed” and “progressed”, while other lipid profile indices, HCT, kidney and liver function 
indices, neutrophil, platelet and daily energy intake were not different between groups, as Table 2 shows. His-
tory of diabetes, hyperlipidemia and hypertension or their treatments was different among groups. Among all 
who experienced MetS regression, NAFLD regressed in 47.6% and among participants, whose MetS progressed, 
NAFLD progression occurred in 18.7%.
Area under the curves (AUC) for differentiating regressed or progressed cases versus others was obtained 
for significant variables extracted from Table 2. Δ-TG was the only variable with AUC greater than 0.70 for dif-
ferentiating regressed cases and based on IDF, with a decrease of at least 40 mg/dl, could predict the disease’s 
regression by 78%. BMI alteration at least 0.28 unit can help to MetS regression, while alteration more than 
1.62 (kg/m2) can predict disease progression. Decreasing WC (at least 8 cm), diastolic blood pressure (at least 
9 mmHg), and FBS (at least 14 mg/dl), could predict MetS regression by 63%, 0.61% and 0.60% respectively, 
based on IDF criteria (Fig. 1, Table 3).
As Table 4 shows the finding of multiple variable analysis, increased Δ-TG (OR 1.01; P < 0.001 and OR 1.01; 
P < 0.001) and Δ-FBS (OR 1.01; P = 0.02 and OR 1.01; P = 0.01) and declining Δ-NLR (OR 0.81; P = 0.04 and OR 
0.79, P = 0.02), and Δ-HDL (OR 0.98; P = 0.05 and OR 0.97; P = 0.001) significantly increased the odds of MetS 
progression based on both IDF and ATP III definitions, respectively.
Declining Δ-TG (OR 0.99; p < 0.001 and OR 0.99; p < 0.001), and increasing Δ-HDL (OR 1.03; p = 0.003 and 
OR 1.03; p = 0.001), significantly increased the odds of MetS regression based on both IDF and ATP III. Other 
variables did not affect the disease regression and progression, significantly.
Table 1.  Baseline correlates of metabolic syndrome, based on IDF and ATP III criteria, in a population-based 
cohort study in Shiraz, Iran. ATP III Adult Treatment Panel III; IDF, International Diabetes Federation. † Chi-
squared test for qualitative variables, ANOVA test for quantitative.
Variable


















mean ± sd) 42.4 ± 12.6 47.7 ± 12.5 45.2 ± 11.5 0.007 42.1 ± 12.4 38.2 ± 13.3 45.8 ± 11.6 0.001
Gender
4.6 (0.10) 3.2 (0.2)Male 179 (75.8) 13 (5.5) 44 (18.6) 173 (73.3) 13 (5.5) 50 (21.2)
Female 208 (68.2) 29 (9.5) 68 (22.3) 209 (68.5) 29 (9.5) 67 (22.0)
Marital status
2.4 (0.3) 2.0 (0.3)Singles 51 (79.7) 4 (6.3) 9 (14.1) 50 (78.1) 4 (6.3) 10 (15.6)
Married 336 (70.4) 38 (8.0) 103 (21.6) 332 (69.9) 38 (8.0) 107 (22.4)
Education
8.6 (0.01) 8.0 (0.02) ≤ 12 years 224 (68.3) 34 (10.4) 70 (21.3) 223 (68.0) 34 (10.4) 71 (21.6)
 > 12yeras 163 (76.5) 8 (3.8) 42 (19.7) 159 (74.6) 8 (3.8) 46 (21.6)
Employment status
7.2 (0.02) 6.0 (0.04)Have job 216 (75.8) 15 (5.3) 54 (18.9) 211 (74.0) 15 (5.3) 59 (20.7)
Have no job 171 (66.8) 27 (10.5) 58 (22.7) 171 (66.8) 27 (10.5) 58 (22.7)
Physical activity‡
2.4 (0.3) 0.9 (0.6)Yes 156 (75.4) 14 (6.8) 37 (17.9) 151 (72.9) 14 (6.8) 42 (20.3)
No 231 (69.2) 28 (8.4) 75 (22.5) 231 (69.2) 28 (8.4) 75 (22.5)
Tobacco smoking
0.01 (0.9) 0.04 (0.9)Yes 74 (71.8) 8 (7.8) 21 (20.4) 72 (69.9) 8 (7.8) 23 (22.3)
No 313 (71.5) 34 (7.8) 91 (20.8) 310 (70.8) 34 (7.8) 94 (21.5)
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Discussion
In this cohort study, association between demographic, social, anthropometric and dietary risk factors with the 
MetS regression or progression were assessed. Based on the univariable analysis, variables of age, Δ-BMI, Δ-WC, 
Δ-FBS, Δ-TG, Δ-Hb, Δ-lymph and Δ-NLR, Δ-SBP, employment status and education were associated with chang-
ing of the disease status while Δ-TG, Δ-FBS, Δ-HDL and Δ-NLR were effective in regression and progression of 
the disease using multiple variable analysis.
Using ATP III as a description of MetS, five more participants were placed in the progressed group in com-
parison to IDF, with no difference to regressed group. ATP III was the most agreed criteria for MetS and the 
most widely  used10. Amongst the Iranian population, IDF definition for MetS is in good correlation with ATP III 
definition, but in low correlation with the WHO  definition11. In the Middle Eastern population, ATP III criteria 
can better predict high CVD risk scores, and IDF criteria is a better predictor of pre-diabetes and diabetes, while 
IDF and ATP III definition provides similar frequency rate of  MetS12. MetS was higher amongst non-diabetics 
who had impaired glucose, using ATP III criteria compare to  IDF12. The two definitions were overlapped for 93% 
of the individuals in defining the occurrence or nonexistence of the MetS in the National Health and Nutrition 
Examination Survey (NHANES)13. When these classifications were applied to an urban population in the United 
States, the IDF criteria categorized 15–20% more adults with MetS than the ATP III  criteria14.
Demographic and social risk factors related to metabolic syndrome regression or progres-
sion. Although gender was not a significant risk factor in our study, there was a significant age factor between 
the three groups. We found that the occurrence of MetS has an association with age. In Marquezine et al.  study15, 
general prevalence of MetS was not significantly different between genders, but a clear relation was established 
between the prevalence and progressing of age. In another study, the prevalence of MetS significantly increased 
with age only among male  participants16, while in other study it increased in both men and  women17.
Table 2.  Baseline para-clinical correlates of metabolic syndrome, based on IDF and ATP III criteria in a 
population-based cohort study in Shiraz, Iran. ALT alanine aminotransferase; AST aspartate aminotransferase, 
ATP III adult treatment panel III; BMI body mass index; BUN blood urea nitrogen; Cr creatinine; DBP diastolic 
blood pressure; FBS fasting blood sugar; Hb hemoglobin; HCT hematocrit; HDL high density lipoprotein-
cholesterol; IDF International Diabetes Federation; Kcal kilocalorie; LDL low density lipoprotein-cholesterol, 
NAFLD non-alcoholic fatty liver disease; NLR neutrophil to lymph ratio; SBP systolic blood pressure; TG 
triglyceride; WC waist circumference. † ANOVA test.
Variable
Metabolic syndrome (IDF definition) Metabolic syndrome (ATP III definition)
Un-changed 
(n = 386) Regressed (n = 42) Progressed n = 112) P-value
Un-changed 
(n = 381) Regressed (n = 42) Progressed (n = 117) P-value
(mean ± sd) (mean ± sd) (mean ± sd) (mean ± sd) (mean ± sd) (mean ± sd)
Δ-TG (mg/dl) − 10.4 ± 69.1 − 62.6 ± 48.3 21.5 ± 77.2  < 0.001 − 12.1 ± 68.1 − 63.8 ± 47.1 25.8 ± 77.5  < 0.001
Δ-LDL (mg/dl) − 11.9 ± 37.6 − 16.4 ± 38.4 − 5.7 ± 38.0 0.2 − 12.3 ± 37.7 − 16.4 ± 38.4 − 4.7 ± 37.5 0.1
Δ-HDL (mg/dl) − 2.4 ± 16.9 1.7 ± 19.2 − 5.3 ± 17.4 0.07 − 2.2 ± 17.6 2.3 ± 18.5 − 6.0 ± 14.8 0.02
Δ-FBS (mg/dl) 1.4 ± 22.5 − 5.1 ± 46.7 10.2 ± 34.9 0.003 1.3 ± 22.3 − 6.8 ± 47.3 11.0 ± 34.4  < 0.001
Δ-BUN (mg/dl) − 0.9 ± 5.4 − 0.6 ± 3.4 − 1.9 ± 10.4 0.3 − 1.0 ± 5.4 − 0.3 ± 3.5 − 1.8 ± 10.2 0.4
Δ-SBP (mm Hg) − 0.3 ± 14.9 − 2.8 ± 15.1 6.4 ± 15.9  < 0.001 − 0.4 ± 14.9 − 3.4 ± 14.8 6.1 ± 15.6  < 0.001
Δ-DBP (mm Hg) 1.6 ± 10.7 − 1.8 ± 8.8 6.4 ± 12.0  < 0.001 1.6 ± 10.8 − 2.2 ± 8.4 6.2 ± 11.8  < 0.001
Δ-Cr (mg/dl) − 0.1 ± 0.3 − 0.1 ± 0.2 − 0.1 ± 0.3 0.9 − 0.1 ± 0.3 − 0.1 ± 0.2 − 0.1 ± 0.3 0.9
Δ-AST (U/L) − 4.3 ± 16.3 − 7.6 ± 13.2 − 4.1 ± 10.6 0.3 − 4.3 ± 16.4 − 7.6 ± 13.2 − 4.0 ± 10.6 0.3
Δ-ALT (U/L) − 4.8 ± 18.7 − 10.1 ± 20.6 − 3.1 ± 14.8 0.1 − 4.9 ± 18.8 − 10.3 ± 20.5 − 2.8 ± 14.6 0.07
Δ-AST/ALT 0.01 ± 0.4 0.02 ± 0.3 0.04 ± 0.4 0.8 0.01 ± 0.4 0.03 ± 0.3 0.02 ± 0.4 0.9
Δ-HCT (%) − 0.2 ± 4.1 − 1.6 ± 6.2 − 0.6 ± 2.7 0.07 − 0.1 ± 4.1 − 1.6 ± 6.2 − 0.7 ± 2.7 0.07
Δ-Neutrophil (%) − 1.1 ± 11.3 − 1.5 ± 10.0 − 3.1 ± 12.0 0.2 − 1.0 ± 11.3 − 1.9 ± 10.4 − 3.1 ± 11.8 0.2
Δ-Lymph (%) 2.9 ± 9.2 2.0 ± 8.6 5.3 ± 7.7 0.03 2.9 ± 9.2 2.1 ± 8.6 5.2 ± 7.6 0.03
Δ-Platelet × 103 
(count/μl) − 16.1 ± 48.6 − 12.6 ± 72.2 − 14.7 ± 54.6 0.9 − 16.9 ± 48.8 − 11.4 ± 72.3 − 12.5 ± 53.8 0.6
Δ-NLR − 0.2 ± 0.9 − 0.2 ± 1.2 − 0.5 ± 1.3 0.04 − 0.2 ± 0.9 − 0.2 ± 1.2 − 0.5 ± 1.3 0.04
Δ-BMI (kg/m2) 0.1 ± 2.5 − 0.9 ± 1.9 0.7 ± 2.4  < 0.001 0.1 ± 2.2 − 0.9 ± 1.9 0.7 ± 2.3  < 0.001
Δ-WC (cm) 7.6 ± 8.4 5.0 ± 6.0 10.5 ± 8.0  < 0.001 7.6 ± 8.4 5.3 ± 5.8 10.0 ± 8.1 0.002
Δ-Kcal (daily intake) 226.2 ± 666.2 247.9 ± 502.7 240.4 ± 791.4 0.9 229.4 ± 662.5 245.1 ± 504 230.3 ± 796.4 0.9
NAFLD n (%)
Un-changed 209 (54.1) 19 (45.2) 61 (54.4) 0.002 207 (54.3) 19 (45.2) 63 (53.8) 0.01
Regressed 110 (28.4) 20 (47.6) 30 (26.7) 107 (28.0) 20 (47.6) 33 (28.2)
Progressed 67 (17.3) 3 (7.1) 21 (18.7) 67 (17.5) 3 (7.1) 21 (17.9)
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In our study, employment and education level as an indication of social status was linked to the MetS in the 
univariable analysis, and similar results were reported in some other studies. Lower social economic status was 
significantly associated with the risk of MetS in women, but not in  men15. The prevalence of MetS was inversely 
associated with education level between  women17.
The occurrence of MetS had significantly increased amongst female blue-collar workers, those with lower 
education level and household  income16. Part-time or temporary workers of either gender showed higher MetS 
prevalence than full-time  workers16, but job rank was not associated with MetS in Mehrdad et al.  study18. The 
prevalence of MetS significantly augmented with being  married16, and smoking  status16,19. The odds ratios (ORs) 
of suffering from MetS was significantly higher amongst people who smoked at least 20 cigarettes/day20. However, 
in our study, smoking states was not significantly different between the groups.
Figure 1.  Cut points and area under ROC Curve (AUC) for para-clinical variables affected. (a) Regressed 
metabolic syndrome groups, based on IDF criteria. (b) Regressed metabolic syndrome groups, based on ATP III 
criteria. (c) Progressed metabolic syndrome groups, based on IDF criteria. (d) Progressed metabolic syndrome 
groups, based on ATP III criteria.
Table 3.  Cut points and area under ROC curve (AUC) for para-clinical variables associated with regression 
and progression of metabolic syndrome. ATP III adult treatment panel III; AUC area under the ROC curve; 
BMI body mass index; DBP diastolic blood pressure; FBS fasting blood sugar; HDL high density lipoprotein-
cholesterol; IDF International Diabetes Federation; SBP systolic blood pressure; TG triglyceride; WC waist 
circumference. a Regressed versus progressed and unchanged. b Progressed versus regressed and unchanged.
Variables
IDF ATP III
Regresseda Progressedb Regresseda Progressedb
Cut point AUC Cut point AUC Cut point AUC Cut point AUC 
Δ-TG (mg/dl) 40 0.78 38 0.63 40 0.79 38 0.66
Δ-BMI (kg/m2) 0.28 0.65 1.62 0.59 0.28 0.64 1.62 0.58
Δ-WC (cm) 8 0.63 11 0.64 8 0.62 11 0.61
Δ-DBP (mm Hg) 9 0.61 5.5 0.61 9 0.63 10 0.61
Δ-FBS (mg/dl) 14 0.60 3 0.60 14 0.62 3 0.62
Δ-SBP (mm Hg) 20 0.56 5.5 0.63 3 0.58 5.5 0.63
Δ-HDL (mg/dl) 11 0.56 2 0.59 11 0.57 2 0.59
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Anthropometric and life style risk factors correlated to the metabolic syndrome regression 
or progression. Δ-WC and Δ-BMI in univariable analysis were significantly different amongst the groups. 
Additionally, Δ-WC increased the odds of disease progression. Abdominal obesity is an indicator of body fat 
which is closely associated with MetS. Therefore, a significant reduction in weight is able to decrease all risk fac-
tors related to MetS, also reducing the risk of type 2  diabetes21.
Studies revealed that just calorie balance could not solve clinical  problems22. Decreasing dietary carbohydrate 
proposed to be an effective way to improve  MetS23,24 and western dietary pattern, increased the occurrence of 
 MetS25. Dietary factors such as energy, carbohydrate, and fat and protein intake were not associated with altering 
MetS status in our population. Additionally, in our study physical activity was not correlated to progression and 
regression of the disease. Although other studies have emphasized on physical activity effect on MetS, its preva-
lence was negatively associated with the level of physical  activity17,20. Different guidelines are currently proposing 
regular, practical, and moderate regimens of physical activity such as 30 min daily moderate-intensity exercise. 
Continuous and regular physical activity is able to decrease all the risk factors associated with  MetS3. Lifestyle 
adjustment and weight loss should be the main principal while treating or avoiding MetS and its  mechanisms26.
Para-clinical parameters associated with metabolic syndrome regression or progression. In 
our study, through a univariable analysis, Δ-FBS, Δ-TG, Δ-HDL, Δ-lymph, Δ-NLR, Δ-SBP and Δ-DBP were 
among the variables correlated with the MetS. Furthermore, in multivariable analysis Δ-FBS, Δ-TG, Δ-HDL 
were significantly associated with the MetS.
Δ-FBS was different between regressed and progressed groups. Since impaired fasting glucose is a component 
of ATP-III and IDF definitions, this finding might not be  surprising3. While MetS and type 2 diabetes (T2D) 
often co-occur, those individuals with MetS without diabetes are at higher risk of developing  diabetes2. Several 
studies have indicated that MetS is a predictor of future  diabetes3.
There was a positive and significant association between MetS diagnosis and some MetS components such as 
TG, HDL and LDL in some studies (gentile, 2008). Comprised of elevated serum TG, small LDL particles, and 
HDL cholesterol, the lipid triad is a constituent of MetS associated with  CAD27. Research has shown that hyper-
triglyceridemia has a strong relationship with atherogenic  factors27. And evidence is stronger for triglyceride as 
a synergistic CAD risk factor among other  dyslipidemias28. Framingham algorithms have shown that many CHD 
events in patients with MetS might be preventable through the control of  lipids9. LDL addressed as a valuable 
marker for diagnosis and severity of the MetS in some  studies29. However, one of the main disruption in MetS is 
the reduction of HDL, which is due to changes in HDL composition and  metabolism3. HDL increase to normal 
levels prevented 25.3 and 27.3% of CHD in men and women, respectively, and the optimal control precluded 51.2 
and 50.6% of the  incidences9. Overall it seems that through the controlling of lipid profile, it would be possible 
to manage CHD in patients with MetS.
Table 4.  Multiple variable analysis of correlates of metabolic syndrome, based on new IDF and ATP III criteria 
in a population-based cohort study in Shiraz, Iran. ALT alanine aminotransferase; ATP III adult treatment 
panel III; BMI body mass index; DBP diastolic blood pressure; FBS fasting blood sugar; Hb hemoglobin; HCT 
hematocrit; HDL high density lipoprotein-cholesterol; IDF International Diabetes Federation; NLR neutrophil 









OR (CI 95%) P-value OR (CI 95%) P-value OR (CI 95%) P-value OR (CI 95%) P-value
Age (year) 1.0 (1.0, 1.0) 0.1 1.0 (1.0, 1.0) 0.004 1.0 (0.9, 1.0) 0.3 1.0 (0.9, 1.0) 0.1
Δ-BMI (kg/m2) 1.2 (0.9, 1.5) 0.1 1.2 (0.9, 1.5) 0.09 0.9 (0.6, 1.3) 0.7 0.9 (0.6, 1.3) 0.7
Δ-WC (cm) 1.2 (0.9, 1.5) 0.1 1.1 (0.8, 1.5) 0.3 1.2 (0.8, 1.9) 0.2 1.2 (0.8, 1.8) 0.3
Δ-TG (mg/dl) 1.0 (1.0, 1.0)  < 0.001 1.0 (1.0, 1.0)  < 0.001 0.9 (0.9, 0.9)  < 0.001 0.9 (0.9, 0.9)  < 0.001
Δ-HDL (mg/dl) 0.9 (0.9, 0.9) 0.05 0.9 (0.9, 0.9) 0.001 1.0 (1.0, 1.0) 0.003 1.0 (1.0, 1.0) 0.001
Δ-FBS (mg/dl) 1.0 (1.0, 1.0) 0.02 1.0 (1.0, 1.0) 0.01 1.0 (0.9, 1.0) 0.8 1.0 (0.9, 1.0) 0.5
Δ-Hb (g/dl) 0.7 (0.5, 1.0) 0.1 0.7 (0.5, 1.0) 0.08 0.8 (0.5, 1.1) 0.2 0.7 (0.4, 1.1) 0.1
Δ-HCT (%) 1.0 (0.9, 1.1) 0.7 1.0 (0.9, 1.1) 0.7 0.9 (0.8, 1.0) 0.6 1.0 (0.8, 1.1) 0.9
Δ-NLR 0.8 (0.6, 0.9) 0.04 0.7 (0.6, 0.9) 0.02 0.9 (0.6, 1.2) 0.6 0.9 (0.6, 1.2) 0.5
Δ-ALT (U/L) 1.0 (0.9, 1.0) 0.5 1.0 (0.9, 1.0) 0.4 0.9 (0.9, 1.0) 0.1 0.9 (0.9, 1.0) 0.5
Δ-SBP (mm Hg) 1.0 (1.0, 1.0) 0.1 1.0 (0.9, 1.0) 0.1 0.9 (0.9, 1.0) 0.7 0.9 (0.9, 1.0) 0.09
Δ-DBP (mm Hg) 1.0 (1.0, 1.0) 0.1 1.0 (1.0, 1.0) 0.09 0.9 (0.9, 1.0) 0.1 0.9 (0.9, 1.0) 0.1
Gender: male/female (as 
reference) 1.0 (0.5, 2.0) 0.9 1.2 (0.6, 2.5) 0.5 1.0 (0.3, 3.1) 0.9 0.9 (0.3, 3.1) 0.9
Educa-
tion: > 12 years/ ≤ 12 years (as 
reference)
1.1 (0.6, 1.9) 0.7 0.9 (0.5, 1.4) 0.6 0.5 (0.2, 1.4) 0.2 0.4 (0.1, 1.2) 0.1
Have job/Have no job (as 
reference) 0.7 (0.3, 1.4) 0.5 0.6 (0.3,1.3) 0.2 0.5 (0.1, 1.5) 0.2 0.4 (0.1,1.4) 0.2
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Reducing the blood pressure down to normal levels, prevented 28.1 and 12.5% of CHD events in MetS men 
and women, respectively. And, controlling it at optimal levels led to preventing CHD to 28.2% and 45.2% of 
events,  respectively9.
Δ-HCT was not different between groups, but Δ-Hb was different between regressed, progressed and un-
changed groups in a univariable analysis. In similar studies, participants with MetS had elevated hemoglobin 
and ferritin  concentration30,31. Higher Hb levels were related to all MetS  mechanisms30. In a large cohort study, 
there was no association between Hb concentration and the incidence of MetS amongst women; however, it was 
a risk factor for the incidence of MetS in  men32.
From the aspects of immunity, lymph and NLR were significantly different in regressed, progressed and 
un-changed groups in our study. We found that decreasing NLR was associated with the disease progression, 
which was not congruent with previous studies. In one systematic review and meta-analysis, including thirty-
eight article, high NLR was significantly associated with the risks of coronary artery disease, acute coronary 
syndrome, stroke and combined cardiovascular  events33; however, at the initial stage of the disease, NLR did 
not correlated with the cardiovascular  determinants34. In Nordestgaard et al.35 study neutrophil and NLR were 
not significant determinants for Myocardial Infarction in the seemingly healthy population. Furthermore, in 
a 9-year cohort study, NLR was not a predictor of hypertension in participants lower than 60 years old, female 
and BMI-specific  groups36.
NAFLD is known as the hepatic expression and a strong determinant of the  MetS37,38. Glucose and triglycer-
ides as the two main components of MetS are produced more by the fatty  liver39 and lead to the development of 
the MetS, which has potentially related to clinical consequences for preventing and handling  MetS38. Around 90% 
of the subjects with NAFLD had ≥ 1 features of metabolic syndrome, and approximately 33% had the complete 
 diagnosis40. In our study more than 47% of people, whose MetS regressed, experienced also NAFLD regression. 
Furthermore, both MetS and NAFLD progressed in 18.7% of participants during the study. According to the 
association between NAFLD and MetS, and high prevalence of NAFLD in  Iran41, considering the factors related 
to NAFLD regression would be valuable to lead MetS regression.
We didn’t assessed the rural that consist about 20% of the province, due to possible difference in their life 
style with urban population. We tried also to use our regional cut point for WC, but due to heterogeneity to 
report about this  parameter42,43, we prefer to use European cut point which is suggested for Eastern Mediter-
ranean and Middle East  populations44. Furthermore, some factors such as genetics, and income could not be 
evaluated easily due to high budget demanding and no appropriate tool respectively. Circadian rhythm was 
not measured in this study as well, should be considered in future studies. Although the sample size was not so 
high because of the nature of the study and the logistic challenges but it was tried to conduct the study with the 
maximum possible logistic and budget capacity while an attempt was made to have a representative sample size 
in the community population by using accurate randomization to introduce different socio-economic classes 
of the community in the study.
Conclusion
After adjusting for confounders, increased TG, FBS and decreased NLR and HDL significantly increased the 
odds of metabolic syndrome progression. Furthermore, declining TG and increasing HDL significantly increased 
the odds of metabolic syndrome regression based on IDF and ATP III definitions. As a practical note, TG and 
HDL can be considered as the most important determinant of metabolic syndrome change. Management of 
hypertriglyceridemia, hyperglycemia, and HDL is a critical, non-invasive and accessible approach to change 
the trend of MetS.
Materials and methods
The present cohort study was conducted in Shiraz, a 2 million populated city in southern Iran, in two phase. A 
multistage cluster random sampling, based on postal codes was performed. Participants were randomly selected 
from residents aged 18 years or older in all the seven postal code districts of Shiraz. These districts consisted of 
different socio-economic groups that more or less are similar to the urban population in the megacities of Iran.
The second phase of this study was carried out and lasted up to 2018, and all the first phase steps were 
repeated. Two physicians and two nurses conducted the interviews, achieved the medical histories and did the 
physical tests. Physicians were gender identical for all participants. Among 819 people who participate the first 
phase, 540 completed phase 2 study. Regarding comparison between who participated and who did not partici-
pate in the second phase of this study, the prevalence of MetS and its components was not significantly different 
between them, except for blood pressure and FBS, which were lower in the dropped out ones.
According to the ATP III and IDF criteria, for diagnose of MetS criteria in the two phase, the participants 
were categorized into three groups: (1) Un-change group (have no MetS at both phase or no change in their MetS 
status) (2) regressed group, which included those who were suffering from MetS in phase 1, but their status had 
improved with no evident MetS in the second phase, (3) progressed group, included participants who had no 
MetS in the first phase but were afflicted with the disease in the second phase. Fourteen participants were known 
case of MetS at first phase also remain in that status in second phase, and we compare statistical parameter of 
this group with healthy group and as we didn’t see any significant difference between them, they were added to 
un-changed group for analysis.
New IDF definition for MetS defines it as having: Central obesity (defined as waist circumference 
(WC) ≥ 91.5 cm for men and ≥ 85.5 cm for women, based on Iranian WC cutoff point for  diagnosing42). Raised 
TG level: ≥ 150 mg/dL (1.7 mmol/L), or specific treatment for this lipid abnormality. Reduced HDL: < 40 mg/dL 
(1.03 mmol/L) in males and < 50 mg/dL (1.29 mmol/L) in females, or specific treatment for this lipid abnormal-
ity. Raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg, or treatment of previously diagnosed 
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hypertension. Raised fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 
 diabetes44.
ATP III for MetS defines as three or more of the following five risk factors: Waist circumference in 
Men > 102  cm (> 40 in), in women > 88  cm (> 35 in), Triglycerides ≥ 150  mg/dL (1.7  mmol/L), HDL in 
Men < 40 mg/dL (1.03 mmol/L), in Women < 50 mg/dL (1.29 mmol/L), Blood pressure ≥ 130/ 85 mm Hg, Fast-
ing glucose ≥ 110 mg/dL (6.1 mmol/L)45.
Measurements. At the baseline, a checklist including demographic, social characteristics and medical his-
tory (includes diseases and medications) were completed via face to face interview. Information such as partici-
pant’s marital status (single/married), education (less/ higher than 12 years), job status (Have job/Have no job) 
and tobacco smoking, alcohol consumption were collected at the baseline. Dietary intake was measured in both 
phase of the study, using a validated, Persian version, food frequency questionnaire (FFQ)46 which were asked 
from participants face to face, filled by trained interviewers and analyzed via Nutritionist-4 software modified 
for Persian food. Participant who has activity for a weekly minimum of 150–300 min of moderate-intensity, 
or 75–150 150 min of vigorous-intensity, or a mixture between the two phases, considered as physically active 
 person47. Physical activity was self-reported by interviewees.
Height was measured by the use of a tape measure to the nearest of 0.1 cm and weight was measured to the 
nearest of 0.1 kg, wearing light clothes. Body Mass Index (BMI) was calculated as weight/height2 (kg/m2). Waist 
circumference was measured as the distance around the waist between the lowest rib and iliac crest and above the 
umbilicus using a non-stretchable tape measure. Diagnosis of non-alcoholic fatty liver (NAFLD) was performed 
via upper abdominal ultrasonography (US) according to the augmented hepatic parenchyma echogenicity with 
the attenuation in the portal vein or diaphragm echogenicity. Using a Shimadzu ultrasound machine (Shimadzu 
Inc., Tokyo, Japan) with a 5-MHz to 7-MHz transducer probe (curvilinear), the trans-abdominal ultrasonography 
was conducted. An expert radiologist performed all the ultrasonogrphic evaluations.
After 8-h fasting, 3-mL blood sample was taken and centrifuged within 30 min after collection and stored at 
− 20 °C until further analysis. Fasting blood sugar (FBS), blood urea nitrogen (BUN), creatinine (Cr), alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), lipid profile consists of triglyceride (TG), low 
(LDL) and high (HDL) density lipoprotein, total cholesterol (Chol), cell blood count (CBC) including hemo-
globin (Hb), hematocrit (HCT), neutrophils, lymphocyte, neutrophil to Lymph ratio (NLR), and platelet were 
measured. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured according to the 
world health organization (WHO) criteria, for each individual in both phase, in sitting and supine position in 
two 15 min apart. The laboratory technician, and laboratory analysis conditions were similar in both phase of 
the study to reduce any bias.
Ethical standards disclosure. This study was conducted according to the guidelines laid down in the 
Declaration of Helsinki and all procedures involving research study participants were approved by the Shiraz 
University of Medical Sciences (SUMS) ethics board committee, reference number: IR.SUMS.REC.1397.312. 
Written informed consent was obtained from all participants and questionnaires were anonymous and encoded. 
For the participants, all processes were free of charge, and interviews were conducted individually by the same 
gender. Participants with diagnosed non-alcoholic fatty liver were referred to a specialist.
Statistical analysis. Analysis was performed by IBM SPSS statistical software version 24. Data are expressed 
as median and frequency percentage. For quantitative variables, differences (phase 2-phase 1, delta: Δ) between 
the two phase of study were calculated. Analysis of variance (ANOVA) and Chi-squared tests were used as uni-
variable analysis. In the next step, variables with P value less than 0.2 in univariable analysis, were entered into 
the multi-nominal logistic regression analysis to examine the odds of regression and progression of MetS, while 
un-changed group was considered as baseline category. Receiver Operating Characteristic (ROC) analysis was 
done for significant variable (p < 0.10). Collinearity among variables was assessed using variance inflation factor 
(VIF) before multivariate analysis and no factors were correlated (VIF < 5). P value less than 0.05 was considered 
significant in all final analysis.
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